This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Tranzyme Pharma Announces Second Quarter 2012 Financial Results

Financial Tables Follow

Tranzyme, Inc.
Consolidated Statements of Comprehensive Income
(Unaudited)
(In thousands, except share and per share amounts)
         
  Three Months Ended Six Months Ended
  June 30, June 30,
  2012 2011 2012 2011
Licensing and royalty revenue  $ 1,340  $ 1,874  $ 2,783 $ 3,771
Research revenue 1,071 1,097 2,236 1,539
Total revenue 2,411 2,971 5,019 5,310
Operating expenses:        
Research and development 5,535 5,681 13,675 10,182
General and administrative 1,880 1,285 3,828 2,256
Total operating expenses 7,415 6,966 17,503 12,438
Operating loss  (5,004)  (3,995)  (12,484)  (7,128)
Interest expense, net  (624)  (399)  (1,056)  (819)
Other income (expense), net 19  (13)  (489)  175
Net income (loss)  $ (5,609)  $ (4,407)  $ (14,029)  $ (7,772)
Net income (loss) per share— basic and diluted  $ (0.23)  $ (0.19)  $ (0.57)  $ (0.67)
Shares used to compute net loss per share— basic and diluted 24,607,888 23,217,146 24,604,595 11,610,927
         
Other comprehensive income (loss):        
Net income (loss)  $ (5,609)  $ (4,407)  $ (14,029)  $ (7,772)
Foreign currency translation adjustment  (62)  (22)  (42)  13
Comprehensive income (loss)  $ (5,671)  $ (4,429)  $ (14,071)  $ (7,759)
 
 
Tranzyme, Inc.
Consolidated Balance Sheets
(Unaudited)
(In thousands, except share and per share amounts)
      
  June 30, December 31,
  2012 2011
Assets    
Current assets:    
Cash and cash equivalents  $ 36,387  $ 40,930
Accounts receivable, net 170 656
Investment tax credits receivable 456 838
Prepaid expenses and other assets 806 1,116
Total current assets 37,819 43,540
Investment tax credits receivable 189 --
Furniture, fixtures and equipment, net 1,069 1,171
Total assets  $ 39,077  $ 44,711
Liabilities and stockholders' deficit    
Current liabilities:    
Accounts payable  $ 2,670  $ 1,971
Accrued liabilities 2,070 1,549
Current portion of deferred revenue 2,930 5,574
Current portion of notes payable 2,169 238
Total current liabilities 9,839 9,332
Notes payable, less current portion 17,517 10,734
Other long-term liabilities 146 163
Total liabilities 27,502 20,229
Total stockholders' equity (deficit) 11,575 24,482
Total liabilities and stockholders' equity  $ 39,077  $ 44,711
CONTACT: Corporate Inquiries:
         Susan Sharpe
         Director, Corporate Communications
         (919) 328-1109
         ssharpe@tranzyme.com
         
         Investor Inquiries:
         David Carey
         Lazar Partners, Ltd.
         (212) 867-1768
         dcarey@lazarpartners.com

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,751.39 +121.12 0.69%
S&P 500 2,108.57 +15.32 0.73%
NASDAQ 5,111.7330 +22.5270 0.44%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs